Tabalumab
- Generic Name
- Tabalumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1143503-67-6
- Unique Ingredient Identifier
- PQP8VH3MJW
- Background
Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Zura Bio initiates Phase II systemic sclerosis treatment trial
Zura Bio launched the Phase II TibuSURE trial for tibulizumab, a dual-antagonist antibody, targeting systemic sclerosis in adults. The trial, involving 80 subjects, evaluates efficacy through mRSS, lung disease, physical function, and rCRISS over 52 weeks. Tibulizumab combines Taltz and tabalumab, aiming for deeper efficacy in autoimmune diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath